DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome

Journal of Neuropathology and Experimental Neurology

Volumn 71, Issue 8, 2012, Pages 702-707

  Motomura, Kazuya ^a   Mittelbronn, Michel ^b   Paulus, Werner ^c   Brokinkel, Benjamin ^c   Keyvani, Kathy ^d   Sure, Ulrich ^d   Wrede, Karsten ^d   Nakazato, Yoichi ^e   Tanaka, Yuko ^e   Pierscianek, Daniela ^a   Kim, Young Ho ^a   Mariani, Luigi ^f,g   Vital, Anne ^h   Ohgaki, Hiroko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e GUNMA UNIVERSITY   (Japan)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g PSI   (Switzerland)

^h CNRS   (France)

Author keywords

Diffuse astrocytoma; DMBT1; IDH1; Primary glioblastoma; Secondary glioblastoma

Indexed keywords

ISOCITRATE DEHYDROGENASE 1;

ADULT; ARTICLE; ASTROCYTOMA; CANCER PROGNOSIS; CHROMOSOME 10Q; DELETED IN MALIGNANT BRAIN TUMOR 1 GENE; DIFFUSE ASTROCYTOMA; FEMALE; GENE; GENE DELETION; GENE FREQUENCY; GENE LOCATION; GENETIC ASSOCIATION; GLIOBLASTOMA; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIMARY GLIOBLASTOMA; PRIORITY JOURNAL; SECONDARY GLIOBLASTOMA; SURVIVAL TIME;

ADULT; ASTROCYTOMA; BRAIN NEOPLASMS; FEMALE; GENE DELETION; GENE DOSAGE; GLIOBLASTOMA; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTORS, CELL SURFACE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84864424322     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0b013e31825f2e5d     Document Type: Article

References (58)

1. Louis DN, Ohgaki H, Wiestler OD, et al, eds. WHO Classification of Tumours of the Central Nervous System. Lyon, France: International Agency for Research on Cancer, 2007
2. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479-89
3. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: A population-based study. Cancer Res 2004;64:6892-99
4. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170:1445-53
5. Nobusawa S, Watanabe T, Kleihues P, et al. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009;15:6002-7
6. Homma T, Fukushima T, Vaccarella S, et al. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol 2006;65:846-54
7. Fujisawa H, Reis RM, Nakamura M, et al. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab Invest 2000;80:65-72
8. Ichimura K, Schmidt EE, Miyakawa A, et al. Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosomes Cancer 1998;22:9-15
9. Karlbom AE, James CD, Boethius J, et al. Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. Hum Genet 1993;92:169-74
10. Ohgaki H, Schauble B, zur Hausen A, et al. Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch 1995;427:113-18
11. Rasheed BK, McLendon RE, Friedman HS, et al. Chromosome 10 deletion mapping in human gliomas: A common deletion region in 10q25. Oncogene 1995;10:2243-46
12. Tohma Y, Gratas C, Biernat W, et al. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 1998;57:684-89
13. Fujisawa H, Kurrer M, Reis RM, et al. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with LOH on chromosome 10q25-qter. Am J Pathol 1999;155:387-94
14. Peraud A, Kreth FW, Wiestler OD, et al. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res 2002;8:1117-24
15. Watanabe K, Sato K, Biernat W, et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 1997;3:523-30
16. Kraus JA, Bolln C, Wolf HK, et al. TP53 alterations and clinical outcome in low-grade astrocytomas. Genes Chromosomes Cancer 1994;10:143-49
17. Schlegel U. p53: An important or most overvalued tumor gene? Laryngol Rhinol Otol 1994;73:651-53
18. al Sarraj S, Bridges LR. p53 immunoreactivity in astrocytomas and its relationship to survival. Br J Neurosurg 1995;9:143-49
19. Kleihues P, Burger PC, Plate KH, et al. Glioblastoma. In: Kleihues P, Cavenee WK, eds. Pathology & Genetics of Tumours of the Nervous System. Lyon, France: International Agency for Research on Cancer, 1997: 16-24
20. von Deimling A, Louis DN, Wiestler OD. Molecular pathways in the formation of gliomas. Glia 1995;15:328-38
21. Cavenee WK, Bigner DD, Newcomb EW, et al. Diffuse astrocytoma. In: Kleihues P, Cavenee WK, eds. Pathology and Genetics of Tumours of the Nervous System. Lyon, France: International Agency for Research on Cancer, 1997:2-9
22. Cancer genome atlas research network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-68
23. Olshen AB, Venkatraman ES, Lucito R, et al. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004;5:557-72
24. Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol 2010;177:2708-14
25. Nobusawa S, Lachuer J, Wierinckx A, et al. Intratumoral patterns of genomic imbalance in glioblastomas. Brain Pathol 2010;20:936-44
26. Nobusawa S, Stawski R, Kim YH, et al. Amplification of the PDGFRA, KIT and KDR genes in glioblastomas: A population-based study. Neuropathology 2011;31:583-88
27. Lv SQ, Kim YH, Giulio F, et al. Genetic alterations in microRNAs in medulloblastomas. Brain Pathol 2012;22:230-39
28. Wu Z, Golub E, Abrams WR, et al. gp340 (SAG) binds to the V3 sequence of gp120 important for chemokine receptor interaction. AIDS Res Hum Retroviruses 2004;20:600-7
29. Hartshorn KL, Ligtenberg A, White MR, et al. Salivary agglutinin and lung scavenger receptor cysteine-rich glycoprotein 340 have broad anti-influenza activities and interactions with surfactant protein D that vary according to donor source and sialylation. Biochem J 2006;393:545-53
30. Ligtenberg AJ, Karlsson NG, Veerman EC. Deleted in malignant brain tumors-1 protein (DMBT1): A pattern recognition receptor with multiple binding sites. Int J Mol Sci 2010;11:5212-33
31. Mollenhauer J, Wiemann S, Scheurlen W, et al. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nat Genet 1997;17:32-39
32. Mollenhauer J, Holmskov U, Wiemann S, et al. The genomic structure of the DMBT1 gene: Evidence for a region with susceptibility to genomic instability. Oncogene 1999;18:6233-40
33. Wu W, Kemp BL, Proctor ML, et al. Expression of DMBT1, a candidate tumor suppressor gene, is frequently lost in lung cancer. Cancer Res 1999;59:1846-51
34. Mollenhauer J, Helmke B, Muller H, et al. Sequential changes of the DMBT1 expression and location in normal lung tissue and lung carcinomas. Genes Chromosomes Cancer 2002;35:164-69
35. Mori M, Shiraishi T, Tanaka S, et al. Lack of DMBT1 expression in esophageal, gastric and colon cancers. Br J Cancer 1999;79:211-13
36. Mollenhauer J, Herbertz S, Helmke B, et al. Deleted in malignant brain tumors 1 is a versatile mucin-like molecule likely to play a differential role in digestive tract cancer. Cancer Res 2001;61:8880-86
37. Braidotti P, Nuciforo PG, Mollenhauer J, et al. DMBT1 expression is downregulated in breast cancer. BMC Cancer 2004;4:46
38. Du J, Guan M, Fan J, et al. Loss of DMBT1 expression in human prostate cancer and its correlation with clinical progressive features. Urology 2011;77:509-13
39. Mollenhauer J, Deichmann M, Helmke B, et al. Frequent downregulation of DMBT1 and galectin-3 in epithelial skin cancer. Int J Cancer 2003; 105:149-57
40. Munoz J, Lazcoz P, Inda MM, et al. Homozygous deletion and expression of PTEN and DMBT1 in human primary neuroblastoma and cell lines. Int J Cancer 2004;109:673-79
41. Somerville RPT, Shoshan Y, Eng C, et al. Molecular analysis of two putative tumour suppressor genes, PTEN and DMBT, which have been implicated in glioblastoma multiforme disease progression. Oncogene 1998;17:1755-57
42. Sasaki H, Betensky RA, Cairncross JG, et al. DMBT1 polymorphisms: Relationship to malignant glioma tumorigenesis. Cancer Res 2002;62: 1790-96
43. Mueller W, Mollenhauer J, Stockhammer F, et al. Rare mutations of the DMBT1 gene in human astrocytic gliomas. Oncogene 2002;21:5956-59
44. Pang JC, Dong Z, Zhang R, et al. Mutation analysis of DMBT1 in glioblastoma, medulloblastoma and oligodendroglial tumors. Int J Cancer 2003;105:76-81
45. Imai MA, Moriya T, Imai FL, et al. Down-regulation of DMBT1 gene expression in human oral squamous cell carcinoma. Int J Mol Med 2005; 15:585-89
46. Munoz J, Castresana JS. Silencing of DMBT1 in neuroblastoma cell lines is not due to methylation of CCWGG motifs on its promoter. Neoplasma 2006;53:15-18
47. Alvarez H, Opalinska J, Zhou L, et al. Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS Genet 2011;7:e1001356
48. Dodurga Y, Avci CB, Yilmaz S, et al. Evaluation of deleted in malignant brain tumors 1 (DMBT1) gene expression in bladder carcinoma cases: Preliminary study. Biomarkers 2011;16:610-55
49. Conde AR, Martins AP, Brito M, et al. DMBT1 is frequently downregulated in well-differentiated gastric carcinoma but more frequently upregulated across various gastric cancer types. Int J Oncol 2007;30:1441-46
50. Okamoto Y, Di Patre PL, Burkhard C, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade astrocytomas and oligodendrogliomas. Acta Neuropathol 2004;108:49-56
51. Shafqat S,Hedley-Whyte ET, Henson JW.Age-dependent rate of anaplastic transformation in low-grade astrocytoma. Neurology 1999;52:867-69
52. van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: Prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry 1998;64:581-87
53. Peraud A, Ansari H, Bise K, et al. Clinical outcome of supratentorial astrocytoma WHO grade II. Acta Neurochir (Wien) 1998;140:1213-22
54. Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: Predictive or prognostic? Clin Cancer Res 2011;17: 4588-99
55. Bourne TD, Schiff D. Update on molecular findings, management and outcome in low-grade gliomas. Nat Rev Neurol 2010;6:695-701
56. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009;27:4150-54
57. Ishii N, Tada M, HamouMF, et al. Cells with TP53 mutations in low-grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor. Oncogene 1999;18:5870-78
58. Watanabe T, Katayama Y, Yoshino A, et al. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course. Clin Cancer Res 2003;9: 4884-90